<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03697512</url>
  </required_header>
  <id_info>
    <org_study_id>IELSG47</org_study_id>
    <secondary_id>2018-002364-44</secondary_id>
    <nct_id>NCT03697512</nct_id>
  </id_info>
  <brief_title>MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas</brief_title>
  <acronym>MALIBU</acronym>
  <official_title>MALIBU Trial - Phase II Study of Combination Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Extranodal Lymphoma Study Group (IELSG)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Extranodal Lymphoma Study Group (IELSG)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single-arm, phase II clinical trial of patients with Extranodal Marginal Zone Lymphoma&#xD;
      (EMZL). It is planned to recruit 130 patients.&#xD;
&#xD;
      Additional patients with Splenic Marginal Zone Lymphoma (SMZL), up to 30, and Nodal Marginal&#xD;
      Zone Lymphoma (NMZL), up to 15, will be included in the trial in order to preliminary explore&#xD;
      the clinical activity and safety of the combination treatment proposed.&#xD;
&#xD;
      The study primary endpoints will be analysed on the EMZL population. Outcome of patients with&#xD;
      SMZL and NMZL will be analysed and reported separately&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Marginal zone lymphomas (MZL) represent a group of indolent B-cell lymphomas that arises from&#xD;
      marginal zone B-cells in extranodal tissues, such as spleen and mucosa associated lymphoid&#xD;
      tissues, and more rarely also in nodal tissues. MZL comprises 5 to 17% of all non-Hodgkin&#xD;
      lymphomas (NHL) in adults. The 2016 World Health Organization (WHO) recognized three separate&#xD;
      subtypes of MZL according to their primary localization, namely the:&#xD;
&#xD;
        1. extranodal MZL (EMZL) of mucosa-associated lymphoid tissue (MALT), also known as MALT&#xD;
           lymphoma&#xD;
&#xD;
        2. splenic MZL (SMZL)&#xD;
&#xD;
        3. nodal MZL (NMZL). These three subtypes are distinct disease entities that are classified&#xD;
           together because they all seem to originate from post germinal centre marginal zone&#xD;
           B-cells.&#xD;
&#xD;
      MALIBU trial is a prospective multicenter trial combining rituximab and ibrutinib in&#xD;
      front-line for patients with MZL, including EMZL, SMZL and NMZL Aim of the study is to assess&#xD;
      the safety and efficacy of the combination of rituximab and ibrutinib in EMZL patients and to&#xD;
      explore its activity in SMZL and NMZL as exploratory subset.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 27, 2019</start_date>
  <completion_date type="Anticipated">June 15, 2027</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Response Rate at 12 months</measure>
    <time_frame>12 months after treatment start</time_frame>
    <description>The proportion of patients with complete response after 12 months from treatment start</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free Survival at 5 years</measure>
    <time_frame>5 years from treatment start</time_frame>
    <description>The proportion of patients without disease progression after 5 years from treatment start</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of treatment-Emerging Adverse Events</measure>
    <time_frame>From the time of informed consent signature until 28 days after treatment discontinuation or until resolution of all treatment-related AEs, whichever occurs later</time_frame>
    <description>Analysis of incidence, severity and relationship of adverse events graded according to NCI Common Toxicity Criteria, version 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response Rate at 24 months</measure>
    <time_frame>24 months from treatment start</time_frame>
    <description>The proportion of patients with complete response after 24 months from treatment start</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate at 12 and 24 months</measure>
    <time_frame>12 and 24 months after treatment start</time_frame>
    <description>The proportion of responding patients (partial and complete responses) assessed at 12 and 24 months after treatment start</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From the date of treatment start to the date of death due to any cause until 5 years from treatment discontinuation</time_frame>
    <description>The time from the date of treatment start to the date of death from any cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">175</enrollment>
  <condition>Marginal Zone Lymphoma</condition>
  <condition>Nodal Marginal Zone Lymphoma</condition>
  <condition>Splenic Marginal Zone Lymphoma</condition>
  <arm_group>
    <arm_group_label>Ibrutinib and Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction PART A, from Day 1 to Day 56.&#xD;
Patients will be treated with:&#xD;
Ibrutinib 560 mg/day continuously up to Day 56;&#xD;
Rituximab 375 mg/m2 intravenously at Day 1, and then subcutaneous (1400 mg, flat dose) at Day 8, 15 and 22 of cycle 1.&#xD;
Induction PART B, from Day 57 to Day 196.&#xD;
Patients will be treated with:&#xD;
Ibrutinib 560 mg/day continuously up to Day 196;&#xD;
Rituximab subcutaneous (1400 mg, flat dose) at Day 1 every 28 days for 4 cycles.&#xD;
Maintenance PART C, from Day 197 to Day 730.&#xD;
Patients will be treated with:&#xD;
- Ibrutinib 560 mg/day continuously up to Day 730.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <description>capsules for oral intake in a dosage of 560 mg (four capsules) daily</description>
    <arm_group_label>Ibrutinib and Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Concentrate solution for infusion - intravenous use; Solution for injection - subcutaneous use.</description>
    <arm_group_label>Ibrutinib and Rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Chemotherapy and immunotherapy-naïve, symptomatic and in need of treatment patients, with&#xD;
        histologically proven CD20-positive MZL, not eligible for local therapy, including:&#xD;
&#xD;
          1. EMZL (MALT Lymphoma) patients with MALT- IPI score 1-2 in need of systemic therapy.&#xD;
&#xD;
             Either de novo or relapsed following local therapy (including surgery, radiotherapy&#xD;
             and antibiotics for H. pylori-positive gastric lymphoma) arisen at any extranodal site&#xD;
             with MALT-international prognostic index (IPI) score 1-2 at the time of study entry.&#xD;
&#xD;
             1.1.The following patients with gastric MALT Lymphoma can be entered:&#xD;
&#xD;
               1. H. pylori-negative cases, either de novo (non pretreated) or at relapse following&#xD;
                  local therapy (i.e., surgery, radiotherapy or antibiotics).&#xD;
&#xD;
               2. H. pylori-positive cases at diagnosis, who either first line antibiotics or&#xD;
                  further local treatment (surgery or radiotherapy), including patients with:&#xD;
&#xD;
                    -  clinical (endoscopic) and histological evidence of disease progression at&#xD;
                       any time post H. pylori eradication;&#xD;
&#xD;
                    -  clinical (endoscopic) and histological relapse (without H. pylori&#xD;
                       re-infection), after a remission patients;&#xD;
&#xD;
                    -  persistent (stable) lymphoma at ≥ 1 year post H. pylori eradication. 1.2.&#xD;
                       Similar consideration may be applied to patients with ocular adnexal&#xD;
                       lymphoma treated with antibiotics.&#xD;
&#xD;
          2. SMZL patients in need of therapy. Either de novo or relapsed following local therapy&#xD;
             [including surgery and antiviral therapy for Hepatitis C virus (HCV)]. Patient must&#xD;
             have a symptomatic disease requiring treatment and be not eligible for splenectomy or&#xD;
             not willing to undergo splenectomy.&#xD;
&#xD;
             2.1. Patients with SMZL can be entered if any of the following criteria is present:&#xD;
&#xD;
               1. bulky progressive or painful splenomegaly;&#xD;
&#xD;
               2. enlarged lymph nodes or involvement of extranodal sites with or without&#xD;
                  cytopenias , i.e. involvement of ≥3 nodal sites, each with a diameter of ≥3 cm.&#xD;
                  Any nodal tumor mass with a diameter of ≥7 cm (GELG criteria, as adopted in&#xD;
                  follicular lymphoma);&#xD;
&#xD;
               3. one of the following symptomatic/progressive cytopenias:&#xD;
&#xD;
                    -  Hgb &lt; 10 g/dL;&#xD;
&#xD;
                    -  ANC &lt; 1000/μL:&#xD;
&#xD;
                    -  PLT&lt; 80 000/μL whatever the reason (autoimmune or hypersplenism or bone&#xD;
                       marrow infiltration).&#xD;
&#xD;
             2.2. Splenectomised patients with rapidly raising lymphocyte counts, lymphadenopathy&#xD;
             or involvement of extranodal sites can be entered.&#xD;
&#xD;
             2.3. SMZL with concomitant HCV infection who have not responded to or are relapsed&#xD;
             after antiviral therapy can be entered.&#xD;
&#xD;
          3. NMZL patients in need of therapy Either, de novo presenting with disseminated disease&#xD;
             or relapsed after local radiotherapy or following antiviral therapy for HCV. Localized&#xD;
             nodal MZL is not eligible.&#xD;
&#xD;
               -  Measurable or evaluable disease.&#xD;
&#xD;
               -  Ann Arbor II-IV. Stage I disease may be eligible only if not candidate to local&#xD;
                  therapy (surgery or radiotherapy).&#xD;
&#xD;
               -  Age ≥ 18.&#xD;
&#xD;
               -  Life expectancy of at least 1 year.&#xD;
&#xD;
               -  ECOG Performance status 0-2.&#xD;
&#xD;
               -  Adequate bone marrow, kidney and liver function&#xD;
&#xD;
               -  For women of childbearing potential only: negative serum pregnancy test done&#xD;
                  within 7 days prior to study drugs administration or within 14 days if with a&#xD;
                  confirmatory urine pregnancy test within 7 days prior to the first study drugs&#xD;
                  administration.&#xD;
&#xD;
               -  Fertile male or female patients of childbearing potential and their partners must&#xD;
                  use higly effective contraception methods during the study and for at least 12&#xD;
                  months after the last dose of subcutaneous rituximab. In case hormonal methods of&#xD;
                  birth control is used a barrier method must be added.&#xD;
&#xD;
               -  Ability to understand and the willingness to sign a written informed consent&#xD;
                  document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any type of lymphoma other than MZL (including MZL with histologic transformation to&#xD;
             high-grade lymphoma).&#xD;
&#xD;
          2. Localized (stage IE and IIE) MALT lymphoma, for example gastric, ocular and cutaneous&#xD;
             lymphoma, that may benefit from local therapy only (surgery or radiotherapy).&#xD;
&#xD;
          3. Known CNS involvement of MZL.&#xD;
&#xD;
          4. Any previous systemic treatment with immunotherapy or chemotherapy or with BTK&#xD;
             inhibitors.&#xD;
&#xD;
          5. Major surgery within 4 weeks prior to registration.&#xD;
&#xD;
          6. History of stroke or intracranial bleeding within 6 months.&#xD;
&#xD;
          7. Known bleeding diathesis (eg, von Willebrand's disease) or hemophilia.&#xD;
&#xD;
          8. Concurrent use of warfarin of other vitamin K antagonists.&#xD;
&#xD;
          9. Concurrent use of strong cytochrome P450 (CYP)3A4/5 inhibitors (see&#xD;
             http://medicine.iupui.edu/clinpharm/ddis/clinical-table/).&#xD;
&#xD;
         10. Any life-threatening illness, medical condition, or organ system dysfunction which, in&#xD;
             the investigator's opinion, could compromise the subject's safety, interfere with the&#xD;
             absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue&#xD;
             risk.&#xD;
&#xD;
         11. International normalized ratio (INR) or prothrombin time (PT) ≥1.5 ULN. Partial&#xD;
             thromboplastin time (PTT) or activated PTT (aPTT) ≥1.5 ULN unless due to lupus&#xD;
             anticoagulant.&#xD;
&#xD;
         12. Vaccinated with live, attenuated vaccines within 4 weeks prior to randomization.&#xD;
&#xD;
         13. Clinically significant hypersensitivity (e.g., anaphylactic or anaphylactoid reactions&#xD;
             to the compound of ibrutinib and/or rituximab themselves or to the excipients in their&#xD;
             formulation).&#xD;
&#xD;
         14. Positive test results for chronic HBV infection (defined as positive HBsAg serology).&#xD;
&#xD;
         15. Patients with occult or prior HBV infection (defined as negative HBsAg and positive&#xD;
             total HBcAb) may be included if HBV DNA is undetectable, provided that they are&#xD;
             willing to undergo monthly DNA testing and taking specific antiviral prophylaxis,&#xD;
             according to local policy. Patients who have protective titers of hepatitis B surface&#xD;
             antibody (HBsAb) after vaccination are eligible.&#xD;
&#xD;
         16. Positive test results for hepatitis C. Patients positive for HCV antibody are eligible&#xD;
             only if PCR is negative for HCV RNA.&#xD;
&#xD;
         17. HIV infection or immunodeficiency.&#xD;
&#xD;
         18. Active, severe infections&#xD;
&#xD;
         19. Pregnancy or breastfeeding.&#xD;
&#xD;
         20. Clinically significant cardiovascular diseases such as uncontrolled or symptomatic&#xD;
             arrhythmias, congestive heart failure, or myocardial infarction within 6 months of&#xD;
             screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by&#xD;
             the New York Heart Association Functional Classification.&#xD;
&#xD;
         21. Any serious medical or psychiatric illness likely to interfere with participation in&#xD;
             this clinical study.&#xD;
&#xD;
         22. Prior history of malignancies other than MZL within 3 years,with the exception of&#xD;
             adequately treated cervical carcinoma in situ or localized non-melanoma skin cancer.&#xD;
&#xD;
         23. Current enrolment or participation in another therapeutic clinical trial within 28&#xD;
             days prior to treatment start&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine Thieblemont, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Saint-Louis Hospital, Paris, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Annarita Conconi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ospedale degli Infermi - Biella, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emanuele Zucca, MD</last_name>
    <phone>+41 (0)91 811 9040</phone>
    <email>ielsg@eoc.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU UCL Namur / site Godinne</name>
      <address>
        <city>Yvoir</city>
        <zip>B5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Andre, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marc Andre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Tours - Hôpital Bretonneau</name>
      <address>
        <city>Tours</city>
        <state>Cedex 01</state>
        <zip>37004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel Gyan, MD</last_name>
    </contact>
    <investigator>
      <last_name>Emmanuel Gyan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <state>Cedex 05</state>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume Cartron, MD</last_name>
    </contact>
    <investigator>
      <last_name>Guillaume Cartron, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU d'Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <state>Cedex 1</state>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Cacheux, MD</last_name>
    </contact>
    <investigator>
      <last_name>Victoria Cacheux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <state>Cedex 9</state>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry Lamy De La Chapelle, MD</last_name>
    </contact>
    <investigator>
      <last_name>Thierry Lamy De La Chapelle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fontanet Bijou, MD</last_name>
    </contact>
    <investigator>
      <last_name>Fontanet Bijou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IHBN - CHU Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ghandi Laurent Damaj, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ghandi Laurent Damaj, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Dijon Bourgogne - Hôpital François Mitterand</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Casanovas, MD</last_name>
    </contact>
    <investigator>
      <last_name>Olivier Casanovas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble - Hôpital Albert MICHALLON</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rémy Gressin, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rémy Gressin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Louis Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Thieblemont, MD</last_name>
      <email>Catherine.Thieblemont@athp.fr</email>
    </contact>
    <investigator>
      <last_name>Catherine Thieblemont, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>PIERRE-BENITE Cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Sesques, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pierre Sesques, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luc-Matthieu Fornecker, MD</last_name>
    </contact>
    <investigator>
      <last_name>Luc-Matthieu Fornecker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IUCT Oncopole Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LoÏc Ysebaert, MD</last_name>
    </contact>
    <investigator>
      <last_name>LoÏc Ysebaert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nancy - Hôpital Brabois</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Feugier, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pierre Feugier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale degli Infermi</name>
      <address>
        <city>Ponderano</city>
        <state>BI</state>
        <zip>13875</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annarita Conconi, MD</last_name>
      <email>annarita.conconi@aslbi.piemonte.it</email>
    </contact>
    <investigator>
      <last_name>Annarita Conconi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrés JM Ferreri, MD</last_name>
    </contact>
    <investigator>
      <last_name>Andrés JM Ferreri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Centro di Riferimento Oncologico di Aviano</name>
      <address>
        <city>Aviano</city>
        <state>PN</state>
        <zip>33061</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Spina, MD</last_name>
    </contact>
    <investigator>
      <last_name>Michele Spina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.U. Città della Salute e della Scienza di Torino Ospedale Molinette</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorella Orsucci, MD</last_name>
    </contact>
    <investigator>
      <last_name>Lorella Orsucci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Ospedali Riuniti - Università Politecnica delle Marche</name>
      <address>
        <city>Ancona</city>
        <zip>60100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guido Gini, MD</last_name>
    </contact>
    <investigator>
      <last_name>Guido Gini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Giovanni Paolo II/I.R.C.C.S. Istituto Tumori</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Attilio Guarini, MD</last_name>
    </contact>
    <investigator>
      <last_name>Attilio Guarini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandra Tucci, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alessandra Tucci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Oncologico Businco</name>
      <address>
        <city>Cagliari</city>
        <zip>09121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria G Cabras, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maria G Cabras, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS - Cà Granda - Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianluigi Reda, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gianluigi Reda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS - Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liliana Devizzi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Liliana Devizzi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AAST Grande Ospedale Metropolitano Niguarda</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandra Tedeschi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alessandra Tedeschi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS - Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luca Arcaini, MD</last_name>
    </contact>
    <investigator>
      <last_name>Luca Arcaini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia AUSL Ravenna</name>
      <address>
        <city>Ravenna</city>
        <zip>48121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Tani, MD</last_name>
    </contact>
    <investigator>
      <last_name>Monica Tani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Arcispedale Santa Maria Nuova IRCCS</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Luminari, MD</last_name>
    </contact>
    <investigator>
      <last_name>Stefano Luminari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Roma La Sapienza</name>
      <address>
        <city>Roma</city>
        <zip>00185</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Pulsoni, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alessandro Pulsoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale di Circolo e Fondazione Macchi di Varese</name>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Merli, MD</last_name>
    </contact>
    <investigator>
      <last_name>Michele Merli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E.</name>
      <address>
        <city>Lisboa</city>
        <zip>1099-023</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Gomes Da Silva, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maria Gomes Da Silva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico della Svizzera Italiana (IOSI)</name>
      <address>
        <city>Bellinzona</city>
        <state>TI</state>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emanuele Zucca, MD</last_name>
      <email>ielsg@eoc.ch</email>
    </contact>
    <investigator>
      <last_name>Emanuele Zucca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonalspital Baden</name>
      <address>
        <city>Baden</city>
        <zip>5404</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronika Ballova, MD</last_name>
    </contact>
    <investigator>
      <last_name>Veronika Ballova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Urban Novak, MD</last_name>
    </contact>
    <investigator>
      <last_name>Urban Novak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Genève</name>
      <address>
        <city>Genève</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen De Ramon Ortiz, MD</last_name>
    </contact>
    <investigator>
      <last_name>Carmen De Ramon Ortiz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thorsten Zenz, MD</last_name>
    </contact>
    <investigator>
      <last_name>Thorsten Zenz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Italy</country>
    <country>Portugal</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 28, 2018</study_first_submitted>
  <study_first_submitted_qc>October 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2018</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

